Failed Dissolution Specifications
Failed Dissolution Specifications
Consumers and healthcare providers should stop using this product immediately. Contact Ascend Laboratories, LLC or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for METOPROLOL SUCCINATE recalls
Be the first to know. Free instant alerts to your inbox.
Ascend Laboratories, LLC, Metoprolol Succinate Extended-Release Tablets, USP, 25 mg* Rx Only, Manufactured by: Alkem Laboratories Ltd., India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-590-01.. Generic: METOPROLOL SUCCINATE ER TABLETS; Brand: METOPROLOL SUCCINATE. Reason: Failed Dissolution Specifications. Classification: Class II. Quantity: 17,304 100-count bottles. Distribution: U.S. Nationwide
Not sure what to do next? Our guide walks you through the process step by step.
Read: How to Get Refunds and ReplacementsGet instant alerts for recalls that affect you. Free forever.
Teva Pharmaceuticals recalled 19,056 bottles of Metoprolol Succinate Extended-Release Tablets, 200 mg, sold nationwide. The recall cites failed dissolution specifications, which could affect how the drug releases in the body. Patients should stop using the product and contact Teva or their healthcare provider for guidance.
Teva Pharmaceuticals recalled 67,043 bottles of Metoprolol Succinate Extended-Release Tablets, 50 mg, distributed nationwide. The FDA enforcement report cites Failed Dissolution Specifications as the hazard. Health care providers and patients should stop using this product immediately and contact Teva for guidance.
Teva Pharmaceuticals recalled 7,448 bottles of Metoprolol Succinate Extended-Release Tablets nationwide after failed dissolution specifications were identified. The recall involves 100 mg, 100‑tablet bottles (NDC 45963-677-11) and 1,000‑tablet bottles (NDC 45963-677-96). The defect may affect drug release and efficacy. Patients should stop using affected bottles and contact Teva or their clinician
Ascend Laboratories recalled Atorvastatin Calcium Tablets USP 40 mg, 90-count (NDC 67877-513-90), 500-count (NDC 67877-513-05), and 1,000-count (NDC 67877-513-10) nationwide in the United States. The batches failed dissolution specifications. Patients should stop using the medication and contact Ascend Laboratories, LLC or their healthcare provider for guidance.